-$0.02 EPS Expected for Antares Pharma Inc (NASDAQ:ATRS) This Quarter

Wall Street analysts expect that Antares Pharma Inc (NASDAQ:ATRS) will report earnings of ($0.02) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Antares Pharma’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.04). Antares Pharma posted earnings of ($0.01) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The firm is expected to announce its next earnings report on Tuesday, November 5th.

On average, analysts expect that Antares Pharma will report full-year earnings of ($0.08) per share for the current year, with EPS estimates ranging from ($0.10) to ($0.05). For the next financial year, analysts forecast that the firm will post earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The business had revenue of $28.43 million for the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.

A number of equities research analysts recently issued reports on ATRS shares. BidaskClub lowered Antares Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $4.50 target price on shares of Antares Pharma in a research note on Monday, May 6th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $5.04.

Shares of NASDAQ:ATRS traded up $0.03 during trading on Thursday, hitting $3.31. 22,044 shares of the stock were exchanged, compared to its average volume of 839,594. The company has a fifty day moving average price of $3.19 and a two-hundred day moving average price of $3.10. The company has a market cap of $539.73 million, a PE ratio of -83.00 and a beta of 0.95. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96.

A number of hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its stake in Antares Pharma by 27.9% in the 4th quarter. Bank of New York Mellon Corp now owns 636,911 shares of the specialty pharmaceutical company’s stock worth $1,733,000 after acquiring an additional 138,756 shares during the last quarter. Raymond James & Associates bought a new position in shares of Antares Pharma during the 4th quarter valued at approximately $102,000. Northern Trust Corp increased its position in shares of Antares Pharma by 0.4% during the 4th quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock valued at $4,738,000 after purchasing an additional 6,868 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Antares Pharma by 11.6% during the 4th quarter. Geode Capital Management LLC now owns 1,609,722 shares of the specialty pharmaceutical company’s stock valued at $4,378,000 after purchasing an additional 167,695 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Antares Pharma by 112.6% during the 4th quarter. Bank of America Corp DE now owns 101,544 shares of the specialty pharmaceutical company’s stock valued at $276,000 after purchasing an additional 53,772 shares during the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Story: What is a Stop Order?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.